Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
10
Today In Oncology
John L Cameron Receives Wangensteen Scientific Forum Award
Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
Considerations on Cancer Drug Development
Inflammatory Activity and Cancer-Related Fatigue in Early Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo